Plain-English translation of NCT03784027 on ClinicalTrials.gov ↗ ·
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial examined whether a fully automated hybrid closed-loop insulin delivery system called CamAPS FX could help very young children with type 1 diabetes keep their blood sugar in a healthier range, compared with standard sensor-augmented pump therapy. The system was designed to work 24 hours a day at home, automatically adjusting insulin delivery based on continuous glucose readings, without requiring constant manual adjustments from parents or caregivers.
Young children with type 1 diabetes often struggle with unpredictable blood sugar swings that are hard for parents to manage, and they are at risk of dangerous low blood sugar episodes. Researchers wanted to see whether an automated system could reduce these risks and improve overall blood sugar control, making life easier for both children and families.
Participants were randomly assigned to use either the automated CamAPS FX insulin delivery system or continue with standard sensor-augmented pump therapy for 16 weeks at home. Those using the automated system wore a small device that continuously monitored blood sugar and automatically delivered insulin, while parents performed daily finger-stick blood glucose checks and uploaded data regularly to the study team. Both groups were monitored for safety, effectiveness, ease of use, and family satisfaction with detailed questionnaires and interviews.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
Austria
Germany
Luxembourg